The topline results for the Anti-Amyloid treatment in Asymptomatic Alzheimer’s disease (A4) study were released today (https://a4study.org). Unfortunately, the drug being investigated, solanezumab, failed to demonstrate a benefit in slowing…
Read More
Dr. Joshua Grill and colleagues at the University of Pittsburgh have been awarded a 3.5 million dollar grant by the National Institute on Aging to advance the field’s understanding of…
Read More
UCI MIND faculty member and psychiatrist, David Sultzer, MD, has been awarded a $12 million dollar grant by the NIA to test a novel prevention treatment. He, along with two…
Read More
On February 17, 2023, a bipartisan group of Senators sent the Secretary of Health and Human Services, Javier Baccera, and the Administrator of the Centers for Medicare and Medicaid Services…
Read More
UCI MIND faculty member and Professor of Neurobiology and Behavior, Mathew Blurton-Jones Jones, PhD, has been awarded Early Career Innovator/Emerging Innovation of the Year by UCI Beall Applied Innovation. Read the…
Read More
Frontotemporal dementia (FTD) is a form of dementia that typically affects individuals in their 50s and 60s. It is therefore, commonly referred to as young onset dementia. Clinically, FTD can…
Read More
Irvine, Calif., Jan. 31, 2023 — Sustained support from philanthropists Joan and Don Beall to the the Institute for Memory Impairments and Neurological Disorders will allow for the continuation of…
Read More
UCI School of Medicine highlighted innovative research performed in the lab of Xiangmin Xu, PhD, UCI MIND faculty member and professor and Chancellor’s Fellow of anatomy and neurobiology in the…
Read More
In a somewhat surprising move, the US Food and Drug Administration (FDA) has declined to grant accelerated approval to Eli Lilly’s donanemab Read the full press release from Eli Lilly…
Read More
The recent FDA approval of lecanemab has generated a lot of buzz in recent days and UCI MIND director, Joshua Grill, PhD has been asked to comment in various highly…
Read More